Enzalutamide Improves Metastasis-Free Survival in Biochemica

Treatment intensification with the androgen receptor inhibitor enzalutamide shows benefit in patients with biochemically recurrent prostate cancer. Data show enzalutamide treatments are safe and effective compared with ADT alone in patients with high-risk biochemically recurrent prostate cancer.

Related Keywords

Stephenj Freedland , Astellas Pharma , Los Angeles , Drug Administration , Pfizer , New England Journal , Law Families Chair , Prostate Cancer , Functional Assessment , Cancer Therapy Prostate ,